Category: biotech

.Actinogen Medical’s cortisol blocker has actually missed the primary endpoint of a period 2 study in anxiety, leaving the Australian biotech to pay attention to

.Actinogen Medical’s hopes– and stock price– have rebounded somewhat coming from earlier this month, when the Australian biotech declared its cortisol blocker had failed to

.Achilles Therapies has actually destroyed its own strategy. The British biotech is actually quiting working on its own clinical-phase cell treatment, checking into manage groups

.Contact it a scenario of great chemistry: Acepodia, a biotech based upon Nobel Champion science, is actually becoming part of a brand new partnership with

.Regardless of izokibep maintaining its newfound winning streak in the medical clinic, Acelyrin is actually no longer paying attention to its former top asset as

.Invite to this week’s Chutes &amp Ladders, our roundup of notable management hirings, shootings as well as retirings around the market. Satisfy deliver the compliment–

.AbbVie has actually gone back to the resource of its antipsychotic powerhouse Vraylar in search of another hit, spending $25 million ahead of time to

.Merely a few brief weeks after succeeding an FDA Fast lane tag for its own investigational BTK degrader in certain blood stream cancers cells, BeiGene

.On the very same time that some Parkinson’s illness medicines are actually being actually brought into question, AbbVie has revealed that its late-stage monotherapy candidate

.In this week’s episode of “The Best Line,” our experts’re diving in to Tough Biotech’s yearly Intense 15 unique document. Ferocious Biotech’s Annalee Armstrong and